Evidence map›Paper›PMID 38708209›Full record

ArticleACS omega2024

New Excipient For Oral Drug Delivery: CNC Derived From Sugarcane Bagasse-Derived Microcrystalline Cellulose.

Shweta Mishra

Abstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Shweta MishraShobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V. L Mehta Road, Vile Parle (W), Mumbai 400056, India.ORCID https://orcid.org/0000-0002-6480-0272

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanocrystalline cellulose (CNC) has emerged as a subject of researcher's interest because of its diverse attributes encompassing biocompatibility, sustainability, a high aspect ratio, and an abundance of -OH groups suitable for modifications. Sugarcane bagasse microcrystalline cellulose (SCBMCC) was used as the raw material for the preparation of CNC due to its pure cellulose content, which is mildly compromised by the pectin, hemicellulose, lignin, and other lignocellulosic components. In the present work, CNC was extracted from SCBMCC and used as a disintegrant. The classic hydrolysis technique was used for the preparation of CNC. Hydrolytic conditions were optimized using the response surface methodology (RSM). The optimized batch of CNC was characterized using techniques such as field-emission scanning electron microscopy (FESEM), transmission electron microscopy (TEM), X-ray diffraction (XRD), and attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy. Notably, CNC prepared under a hydrolysis time of 90 min exhibited the highest crystallinity of 69.9%. The average particle size and zeta potential were found to be 145 nm and -34.4 mV, respectively. Thermal analysis suggested that an intermediate hydrolysis time resulted in CNC with enhanced thermal stability, showcasing its potential for pharmaceutical applications. Diclofenac potassium was used as the model drug to evaluate the disintegrant properties of CNC as an excipient. Tablets were prepared using the direct compression method. SCBMCC and CNC were used as disintegrants and were compared with the commercial product. The disintegration times (DTs) attained for the tablets prepared using CNC and SCBMCC are 219 and 339.83 s, respectively. The dissolution study of CNC showed a dissolution efficacy (DE%) of 66 and a mean dissolution time (MDT) of 12. The research findings showed that tablets prepared using CNC as disintegrants exhibited the fastest disintegration compared to other formulations.

Identifiers

PMID38708209
PMCPMC11064190

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.